Fulcrum Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Fulcrum Therapeutics, a clinical-stage biopharmaceutical company focused on genetically defined rare diseases, announced its upcoming participation in two virtual investor conferences. The SVB Leerink 10th Annual Global Healthcare Conference is scheduled for February 25, 2021, at 10:40 a.m. ET. The H.C. Wainwright Global Life Sciences Conference will feature a prerecorded fireside chat on March 9, 2021, at 7:00 a.m. ET. Audio webcasts will be accessible through the Investor Relations section of the Fulcrum website for 90 days after each event.

CAMBRIDGE, Mass., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in the following virtual investor conferences:

• Virtual SVB Leerink 10th Annual Global Healthcare Conference
  Presentation on Thursday, February 25, 2021 at 10:40 a.m. ET.

• Virtual H.C. Wainwright Global Life Sciences Conference
  Prerecorded Fireside Chat Available on Tuesday, March 9, 2021 at 7:00 a.m. ET.

Audio webcasts of the presentations will be available through the Investor Relations section of the Fulcrum website at https://ir.fulcrumtx.com/events-and-presentations. Archived replays will be available on the Company’s website for 90 days after each conference.

About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and Phase 3 for the treatment of COVID-19. Fulcrum has also advanced FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and beta thalassemia into Phase 1 clinical development.

Please visit www.fulcrumtx.com.

Contact:
Christi Waarich
Director, Investor Relations
and Corporate Communications
617-651-8664
cwaarich@fulcrumtx.com

 

FAQ

What is the date of Fulcrum Therapeutics' upcoming investor conference?

Fulcrum Therapeutics will participate in the SVB Leerink 10th Annual Global Healthcare Conference on February 25, 2021.

When is the H.C. Wainwright Global Life Sciences Conference for Fulcrum Therapeutics?

The H.C. Wainwright Global Life Sciences Conference will feature a prerecorded fireside chat on March 9, 2021, at 7:00 a.m. ET.

Where can I find the audio webcasts of Fulcrum Therapeutics' presentations?

Audio webcasts will be available on Fulcrum Therapeutics' Investor Relations website for 90 days after each conference.

What diseases does Fulcrum Therapeutics focus on?

Fulcrum Therapeutics focuses on genetically defined rare diseases, including facioscapulohumeral muscular dystrophy and sickle cell disease.

What clinical stages are Fulcrum's products currently in?

Fulcrum's product losmapimod is in Phase 2 for facioscapulohumeral muscular dystrophy and Phase 3 for COVID-19. FTX-6058 is in Phase 1 for sickle cell disease.